Advertisement

PharmacoEconomics & Outcomes News

, Volume 825, Issue 1, pp 5–5 | Cite as

Alectinib not cost effective for NSCLC in China

Clinical study
  • 6 Downloads

Reference

  1. Guan H, et al. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. Advances in Therapy : 12 Mar 2019. Available from: URL: http://doi.org/10.1007/s12325-019-00908-7

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations